Product Description
CT-262, a first-in-its-class treatment for solid and hematological tumors. Cairn holds the exclusive worldwide license to CT-262, which was invented at Scripps Research using unique medicinal chemistry to create a highly potent DNA alkylating agent that preferentially activates in cancer cells. In vitro and in vivo animal oncology models have shown CT-262 to produce markedly better efficacy and safety results than current first-line therapies and highlight the potential to replace these compounds in a broad array of cancers. (Sourced from: https://www.linkedin.com/company/cairn-therapeutics/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cairn Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Hematological Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|